Skip to main content

Home/ Health and Fitness Club/ Group items tagged clinical-research

Rss Feed Group items tagged

pharmacybiz

NHS England's Bold Plan for Clinical Academic Training by 2030 - 0 views

  •  
    The NHS England last week released a survey report on the involvement of pharmacy professionals in research, and proposed the implementation of a clinical academic training pathway for pharmacy professionals by 2030. Recommendations were made to support the embedding of research at all stages of a pharmacy professional's career. The report presented the findings of two surveys that NHS England launched in May 2022, one for individual pharmacy professionals and one for organisations, calling for evidence on clinical academic careers in pharmacy. The survey found that only a minority of the pharmacy workforce take up clinical research training opportunities. "Just under a quarter of individual respondents had applied for the National Institute of Health and Care Research (NIHR) or other research project grants, and just under half of the organisational survey respondents had supported individuals to apply for such a grant," it said.
pharmacybiz

DHSC New NIHR RDN Transforming UK Research - 0 views

  •  
    The Department of Health and Social Care (DHSC) has created a new NIHR Research Delivery Network (RDN) to support the successful delivery of health and social care research in England. The network, which will start operating from next year, will play a critical and active role in implementing government policies. It will support in implementing the Life Sciences Vision, the Future of UK Clinical Research Delivery vision, and policy for life sciences research and development. The new network would be mainly working on growing the amount of commercial clinical research as its key strategic ambition. Also, NIHR RDN will be responding to the findings of the Lord O'Shaughnessy review, which set out a clear blueprint for how the UK can return to its global leadership role.
pharmacybiz

Revolutionizing Cancer Treatment: mRNA Therapy Breakthrough UK - 0 views

  •  
    Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.
pharmacybiz

Kanabo Revolutionary Pain Clinic in Partnership with City Dock Pharmacy - 0 views

  •  
    Kanabo Group plc, a medical cannabis research and development company, has entered into a partnership with City Dock Pharmacy in London to introduce a walk-in clinic for pain management. The pain clinic will cater to patients who are eligible for alternative therapies (when traditional treatments have failed to deliver improvements), and will offer specialised medicines, including medicinal cannabis. When it opens, the new facility at City Dock Pharmacy in Wapping will become the UK's first walk-in clinic for pain management, but it will also deliver appointment-related services, the companies said. The partnership is part of the London-based company's wider ambition to extend its reach into physical pharmacies throughout the UK, and its plans to replicate this model across other pharmacies.
kyra smith

Pre-clinical and clinical research: Part of drug development process - 0 views

  •  
    Phases of Clinical development Clinical research determines the safety and efficacy of medications, devices, diagnostic products and treatment regimens discovered for the human use in terms of prevention, treatment, diagnosis or for relieving symptoms of a disease. Successfulness of the pre-clinical research and approval from the regulatory authority are the mandatory requirements for the clinical trials.
pharmacybiz

New PRSB Chair: Professor Reecha Sofat to Drive Data Standards in Healthcare - 0 views

  •  
    The Professional Records Standards Body (PRSB), which develops information standards for health and social care records, has appointed Professor Reecha Sofat as the new Chair. She will assume the role at the end of October 2024, succeeding Professor Maureen Baker CBE, who will step down after seven years as Chair of the PRSB. A Clinical Pharmacologist, Professor Sofat has held many leadership roles across the NHS, academia and scientific societies. Professor Sofat is Breckenridge Chair of Clinical Pharmacology at the University of Liverpool. She practices general internal medicine and is also an Associate Director at the British Heart Foundation (BHF) Data Science Centre (DSC) which is led by Health Data Research UK (HDRUK). With a passion for data science and extensive clinical and research insights, Professor Sofat is focused on embedding research into routine health and social care. She said: "I am passionate about using the rich health data that is already collected across NHS and social care to better understand the causes and consequences of disease and improve health outcomes.
pharmacybiz

Alzheimer success research unlocks hope for future therapies - 0 views

  •  
    The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.
AMVital Nutrition

Does Ginger Help With Nausea? | AMVital - 0 views

  •  
    Ginger is an age-old herb that has had extensive usage in history for its numerous natural therapeutic effects, especially as an "anti-emetic." The best-known proof indicates that ginger is an effective and affordable remedy for nauseatic and vomiting ailments and is safe. The pleasing zesty "kick" from the root of Zingiber officinale, the ginger plant, is what produces ginger ale, ginger tea, sweets, loaves of bread, and many Asian dishes so delicious. Ginger adds an aromatic tang to both sweet and spicy foods. As ginger is frequently suggested for its stomach-settling impacts, you may wonder whether it's a proven way to treat nauseatic ailments naturally. This article reevaluates the efficacy and safety of ginger for nausea and the most promising practices for using it. How does Ginger Help with Nausea? According to PubMed Central, the highly appreciated database from the National Institutes of Health, it's believed that ginger fetches its therapeutic qualities from gingerol, the main bioactive ingredient in fresh ginger, and complementary blends called shogaols, which provide the root its savory flavor. Shogaols are more robust in dried ginger, with 6-shogaol as the primary source of antioxidants. At the same time, gingerols are more plentiful in raw ginger. Some examination has revealed that ginger and its compounds may improve digestive function and speed up stomach emptying feel, relieving nausea. Its anti-inflammatory traits may improve digestive activity and sustain the discharge of blood-pressure-regulating hormones to relax your body and ease nausea. Other Health Benefits of Ginger Being an anti-inflammatory, antioxidant, and digestive aid, it has been used as a natural treatment for helping to alleviate nausea and other symptoms. It can be used to treat: Heartburn Indigestion Motion sickness Reduce joint pain Soothe sore throats Minimize the duration of colds and flu viruses Ease menstrual cramps Prevent cancer cell growth Improve choleste
pharmacybiz

Community Pharmacy: Embrace it as Vital Clinical Service - 0 views

  •  
    Politicians, researchers and pharmacy leaders called on the government to make community pharmacy a fundamental part of clinical services at an event at the House of Commons on Wednesday (13). At the launch of a research publication carried out by the University of Bath in conjunction with Sigma Pharmaceuticals, community pharmacy was described as an "essential pillar of health care provision" in the UK. The aim of this research was to provide evidence to support a strategy for the future developments of community pharmacy to ensure the sector continues to meet the needs of the public in the NHS. Researchers analysed 25 health and community pharmacy related policies published by the department of health, the NHS, the pharmacy profession, and spoke to stakeholders from a wide range of backgrounds, including patients, pharmacists, NHS commissioners and GPS.
pharmacybiz

OCTP's Cannabis-Derived Drug Reaches Phase 1 Milestone - 0 views

  •  
    Oxford Cannabinoid Technologies Holdings plc, which specialises in developing cannabis-derived medicines with pain-relieving properties, has successfully administered the first-in-human dose of its lead pharmaceutical drug compound, OCT461201, in its phase 1 clinical trial. The company holds a portfolio of four drug candidates intended for use as licensed pain medications. The drug is a selective cannabinoid receptor type 2 agonist with the potential to treat chemotherapy-induced peripheral neuropathy and irritable bowel syndrome. The UK trial, conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd., is progressing with healthy volunteers, OCTP said in a statement. Using a single ascending dose protocol, the primary objective is to demonstrate OCT461201's safety and tolerability, while providing information on its pharmacokinetic profile, to confirm its value as a potential drug. Results from the trial, funded entirely by OCTP's existing resources, are expected in the third quarter of 2023, the statement added.
pharmacybiz

Katie Maddock is new chair of Pharmacy Schools Council - 0 views

  •  
    he Pharmacy Schools Council (PhSC) has elected Professor Katie Maddock as the organisation's new chair. Prior to becoming head of school at Keele University, Professor Maddock had been MPharm course director and associate dean for education for the Faculty of Medicine and Health Sciences, responsible for developing the clinical teaching at Keele. Before joining Keele University, she taught clinical pharmacy and pharmacy practice at Aston University. Her research interests lie in pharmacy education, particularly the use of technology in teaching, clinical therapeutics, augmented reality simulation and interprofessional education. She was also awarded a principal fellowship of the Higher Education Academy in November 2020. Having worked in hospital pharmacy, Professor Maddock is acutely aware of the pressures that Covid-19 has placed on healthcare, as well as the importance of retaining and building upon the positive changes to patient care and pharmacy practice that were developed in response to the pandemic.
pharmacybiz

Eli Lilly drug slows Alzheimer's by 35%:Company - 0 views

  •  
    An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.
pharmacybiz

Career Tips: 8 Ways To Help You Start In The Medical Field - 0 views

  •  
    Are you looking to start a career in the medical field but don't know where to begin? There are many different paths to choose from when it comes to entering the medical profession. It can be daunting trying to figure out which one is right for you. But with some research, planning, and dedication, you can find your way into this rewarding and fulfilling industry. Here are 8 tips that will help get you started on your journey toward becoming a successful healthcare professional. 1. ONLINE PROGRAMS If you have already decided on a career path and need to obtain additional qualifications or knowledge, there are many online programs available for medical professionals. These courses provide students with the opportunity to learn from home and gain experience in their chosen field without sacrificing the quality of education. You can find an online medical assistant programs, medical biller and coding programs, lab technician training, and more. It's important to research each program and make sure it's accredited before enrolling. While online programs may not offer the same hands-on experience as a traditional school, they can be an affordable and convenient way to get your foot in the door. 2. VOLUNTEERING OR WORKING IN A CLINICAL SETTING Volunteering or working part-time in a clinical setting is an excellent way to gain experience and decide if the medicine is the right profession for you. Even volunteer work can provide invaluable insight into how the medical field works, allowing you to network with professionals, observe procedures and treatment methods, and develop skills from patient interaction. Additionally, any volunteer work or job experience related to healthcare that appears on your resume establishes you as a serious candidate for a career in medicine. While you are likely to find many volunteer opportunities, be sure to do your research and only take positions in reputable organizations.
AMVital Nutrition

Turmeric Soap: Are you curious Why is it so good for you? - AMVital - 0 views

  •  
    Organic Turmeric powder has long been used as a natural beauty agent as it is used to make a paste and face masks for treating various skin issues till now. As per the latest research, turmeric Soap helps banish dark spots and hyperpigmentation. Also, a study published in the journal of clinical and aesthetic dermatology affirms that topical turmeric curcumin extract in a moisturizing cream and soap formula reduces the appearance of facial spots, fine lines, aging, and wrinkles on human facial skin. Also, it was found that hyperpigmentation can be reduced by 14-15% within four to five weeks of turmeric-based skincare products. Being a natural ingredient, turmeric soap is safe for all skin types and is even recommended for people with skin conditions. So let's further explain why this is so good for you. Naturally, turmeric is rich in antioxidants and antibacterial properties. The antibacterial and antioxidant content in turmeric battle acne, whereas the mighty antioxidant makes the skin tone clear. And the same properties go for turmeric used in soaps. Is turmeric soap good for your face? Yes, turmeric soap is virtually good for your face because modern dermatologists have explored its positive and healthy effects on the skin. On the other hand, it is becoming famous because of its beneficial impacts on the skin. Turmeric soap benefits for skin Backed by clinically proven research, this skin-healthy soap has the following benefits: 1. Antiseptic, Anti-bacterial & Anti-inflammatory Soap Turmeric is a known herb that treats acne. This is because it boasts natural antiseptic and anti-inflammatory qualities that prevent clogged pores and stop the growth of acne-causing bacteria while reducing redness and inflammation. As an anti-inflammatory agent, it can help calm the skin and prevent long-term acne scars. Anti-bacterial content in turmeric arrest acne breakout and prevents further infection both for skin as well as oral health. You must add this soap to your ski
AMVital Nutrition

Is Ginger Good for Colds? Here's the Proof- AMVital - 0 views

  •  
    As the weather gets colder, we're all looking for ways to get through the winter months. One of the most popular natural remedies is ginger. It's been used for thousands of years and has been shown to relieve symptoms like sore throat and coughing as well as boost overall health. People often use ginger as a home remedy for treating colds and sore throats due to its antibacterial markers that can help handle pain and inflammation. The Ginger (Zingiber officinale) root is a perennial plant. Our forefathers have consumed ginger as a herbal therapy for decades after decades to cure many health conditions, from arthritis to abdominal pain. Today, we often use ginger when we have a cough or cold. The scientific database reveals that ginger has medicinal effects that could ease the symptoms of a cold or sore throat. This article will examine how ginger may help colds and how you can use it in teas, juices, and other home remedies. How is ginger good for treating Colds? There is no definitive proof that ginger can cure or eliminate colds from roots, but research indicates that it may help control them. Ginger can also aid in improving cold symptoms. One study review shows that there is evidence that ginger can help: prevent colds control or relieve a sore throat ease congestion decrease inflammation However, researchers need to examine ginger's additional benefits to support this evidence. Medicinal properties Ginger has blends called gingerols and shogaols. Experimenters consider that these compounds give ginger its therapeutic properties. It is a potent anti-inflammatory. It's also a natural expectorant and decongestant, which helps to clear up congestion. Ginger is high in vitamin C and manganese, both essential nutrients for boosting your immune system during the cold season. While ginger may not be a cure-all for the common cold or flu (it's always best to consult your doctor if you're sick), it can help keep you feeling better while you recover. Stu
pharmacybiz

AMR research : Government allocates £39 million - 0 views

  •  
    The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.
pharmacybiz

£260m to boost healthcare research and manufacturing : Govt - 0 views

  •  
    The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and diagnostics. Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy. This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated. The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier and better diagnostic technologies, to medical devices. The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.
pharmacybiz

Alzheimer's :Sugar molecule in blood can predict - 0 views

  •  
    Early detection and treatment of Alzheimer's disease require the use of dependable and cost-effective screening technologies. Researchers at Sweden's Karolinska Institutet have revealed that the level of tau, a protein that plays a vital role in the development of severe dementia, is associated with a kind of sugar molecule in the blood. The study, which is published in Alzheimer's & Dementia, can pave the way for a simple screening procedure able to predict onset ten years in advance. "The role of glycans, structures made up of sugar molecules, is a relatively unexplored field in dementia research," says the study's first author Robin Zhou, medical student and affiliated researcher at the Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet. "We demonstrate in our study that blood levels of glycans are altered early during the development of the disease. This could mean that we'll be able to predict the risk of Alzheimer's disease with only a blood test and a memory test." In Alzheimer's disease, the neurons of the brain die, which is thought to be a result of the abnormal accumulation of the proteins amyloid beta and tau. Clinical trials for Alzheimer's drugs show that treatment should commence early in the pathological process, before too many neurons have died, to reverse the process before it is too late.
pharmacybiz

Gum Disease to Increased Stroke Risk in Young Adults : Study - 0 views

  •  
    Researchers from King's College London and the University of Helsinki have identified a link between periodontitis (gum disease) and cryptogenic ischemic stroke, which causes a blockage in the blood vessel supplying blood to a region of the brain. The findings, recently published in the Journal of Dental Research, emphasise severe gum disease as a risk factor for young-onset stroke, particularly in patients with no other identifiable risk factors. Dr. Susanna Paju, Periodontology Specialist from the University of Helsinki, led the study in collaboration with Dr. Svetislav Zaric, Clinical Lecturer in Periodontology from King's College London. Dr. Zaric explains the implications of their research: "Stroke remains the second leading cause of death globally. Strikingly, the incidence and prevalence of ischemic stroke have been increasing in the younger population during past decades," she said. "Periodontitis, which involves deep inflammation of the gums due to bacteria under the gumline, can lead to systemic effects as bacteria enter the bloodstream and affect other parts of the body," she added.
Bharatbookbureau MarketReport

Cholera Global Clinical Trials Review - 0 views

  •  
    Elemental information and data relating to the clinical trials on Cholera and includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.
1 - 20 of 56 Next › Last »
Showing 20 items per page